Publications

Vaccination with a lymph node targeted Amphiphile‐CpG adjuvant promotes potent cellular and humoral immunity to SARS‐CoV‐2 protein subunit antigens
Peter DeMuth, PhD, Vice President of Research — Vaccines Summit 2021 » Read more
Approaches to Improve the Clinical Performance of Genetically Engineered T Cells
» Read more
Combined PET and Whole Tissue Imaging of Lymphatic Targeting vaccine in NHPs
Antigen accumulation in lymph nodes (LNs) is critical for vaccine efficacy, but understanding of vaccine biodistributionin humans or large animals remains limited. » Read more
Exploiting albumin as a mucosal vaccine chaperone for robust generation of lung-resident memory T cells
Tissue-resident memory T cells (TRMs) can profoundly enhance mucosal immunity, but parameters governing TRM induction by vaccination remain poorly understood. » Read more
A lymph node–targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2
Science Advances Martin P. Steinbuck, Lochana M. Seenappa, Aniela Jakubowski, Lisa K. McNeil, Christopher M. Haqq*, Peter C. DeMuth The profound consequences of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mandate urgent development of effective vaccines. Here, we evaluated an Amphiphile (AMP) vaccine adjuvant, AMP-CpG, composed of diacyl lipid–modified CpG, admixed with the SARS-CoV-2 Spike-2 receptor […] » Read more
World Vaccine Congress: A lymph node targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2
The SARS-CoV-2 pandemic’s public health, economic, and social impacts mandate urgent development of effective vaccines to contain or eradicate infection. To that end, we evaluated a novel amphiphile (AMP) vaccine adjuvant, AMP-CpG, composed of diacyl lipid-modified CpG, admixed with the SARS-CoV-2 Spike-2 receptor binding domain (Spike RBD) protein for immunization (ELI 005). » Read more
RAS Summit: Targeting the lymph nodes to enhance mutant KRAS-specific vaccine responses
» Read more
A lymph node targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2
The SARS-CoV-2 pandemic has led to public health, economic, and social consequences that mandate urgent development of effective vaccines to contain or eradicate infection. To that end, we evaluated a novel amphiphile (AMP) vaccine adjuvant, AMP-CpG, composed of diacyl lipid-modified CpG, admixed with the SARS-CoV-2 Spike-2 receptor binding domain protein as a candidate vaccine (ELI-005) […] » Read more
A lymph node targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2
» Read more
Orchestrating the immune system for precision immunity — Elicio’s lymph node-targeting Amphiphile technology delivers potent T cell activation and boosts the effects of engineered cell therapies
Immune cells are naturally gifted in recognizing antigens and fighting off infection and disease. But, just like talented people, they need nurturing and the right training to fulfil their true potential. For immune cells this means a spell in lymph nodes— the training camps of the immune system—where they receive specialized instruction in the art of immune surveillance and attack. » Read more
Boosting engineered T cells
» Read more
Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor
» Read more
Enhancement of peptide vaccine immunogenicity by increasing lymphatic drainage and boosting serum stability cancer immunology research
Antitumor T-cell responses have the potential to be curative in cancer patients, but the induction of potent T-cell immunity through vaccination remains a largely unmet goal of immunotherapy. » Read more
Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses
Nature Medicine » Read more
Structure-based programming of lymph-node targeting in molecular vaccines
Nature » Read more